Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer.

McPhillips, F; Mullen, P; Monia, B P; Ritchie, A A; Dorr, F A; Smyth, J F; Langdon, S P

McPhillips, F; Mullen, P; Monia, B P; Ritchie, A A; Dorr, F A; Smyth, J F; Langdon, S P.

Affiliation

McPhillips F; ICRF Medical Oncology Unit, Western General Hospital, Edinburgh, EH4 2XU, UK.

Br J Cancer ; 85(11): 1753-8, 2001 Nov 30.

Article in En | MEDLINE | ID: mdl-11742498

Subject(s)

DNA, Antisense/pharmacology; Ovarian Neoplasms/drug therapy; Proto-Oncogene Proteins c-raf/drug effects; Animals; Cell Cycle/drug effects; Cell Cycle/physiology; Cell Division/drug effects; DNA, Antisense/therapeutic use; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms/metabolism; Ovarian Neoplasms/pathology; Proto-Oncogene Proteins c-raf/biosynthesis; Proto-Oncogene Proteins c-raf/genetics; Survival Analysis; Time Factors; Xenograft Model Antitumor Assays

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / DNA, Antisense / Proto-Oncogene Proteins c-raf Type of study: Prognostic_studies / Risk_factors_studies Limits: Animals / Female / Humans Language: En Journal: Br J Cancer Year: 2001 Document type: Article

Fulltext

XML

PubMed Links

Search on Google